Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Executive Summary

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

You may also be interested in...



GSK On Track For Six Regulatory Submissions In The Second Half

R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.

Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.

 

AZ Lynparza Head Hopes 2020 Will See PARP Inhibitor Treating Pancreatic Cancer

AstraZeneca and Merck & Co hope Lynparza will soon have a third treatment indication after their PARP inhibitor became the first to demonstrate a benefit in germline BRCA-mutated metastatic pancreatic cancer, having hit targets in the Phase III POLO trial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel